Estudo randomizado | Darolutamida e sobrevida no câncer de próstata metastático e sensível a hormônio.
19 Fev, 2022 | 13:58h
Comentário no Twitter
Adding darolutamide to androgen-deprivation therapy and docetaxel significantly increased overall survival among patients with metastatic, hormone-sensitive prostate cancer. #GU22 https://t.co/GkQZdKgtJs pic.twitter.com/3e5S7tW1Zw
— NEJM (@NEJM) February 17, 2022